Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: Indicated Homoeopathic medicine: Homoeopathic drugs as detailed in the standard Homoepathic Materia Medica and in the Homoeopathic Pharmacopoeia (India/US) will be used in the study on
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: 1 At least 3month history of Psoriasis 2 All types of psoriasis 3 No drug dependence 4 No medication for psoriasis (both oral and local) for at least 6 weeks in succession till date • Mild/moderate/Severe cases as per PASI Score • Willing to give informed consent
Exclusion criteria
Exclusion criteria: • Ongoing treatment/medication for Psoriasis, of any medical discipline both oral and/ local or phototherapy. • Evidence of skin conditions (i.e eczema, lichen planus, teania) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasisPregnant ladies or breast-feeding women. • On treatment for any systemic infection , inflammatory, autoimmune disorder, malignancy, or any type of drug dependence like diabetes, hypertension, thyroid medications or any other disease like asthma, allergic disease etc • Known kidney function disorder. • Persons taking calcium, vitamin D supplements or vitamin D-like medicines ?? • Very severe cases as per PASI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Serum levels of Th17 derived cytokines (IL-17A, IL-17F, IL-17A/F and IL-22), IL-33 at day 0, 180 and 360 during course of homoeopathic treatment for Psoriasis using ELISA based on PASI scoring. 2. PASI score at day 0, 180, 360 during course of homoeopathic treatment for Psoriasis. Timepoint: 1. Serum levels of Th17 derived cytokines (IL-17A, IL-17F, IL-17A/F and IL-22), IL-33 at day 0, 180 and 360 during course of homoeopathic treatment for Psoriasis using ELISA. 2. PASI score at day 0, 180, 360 during course of homoeopathic treatment for Psoriasis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. m-RNA expression of Th17 derived cytokines, IL-33 along with its receptor sST2 in PBMCs of patients at day 0,180 and day 360 using Real Time PCR. 2. Quality of life by change in Dermatology Life quality Index at Day 0, 180, 360. 3. Proportion (%) of enrolled participants achieving a PASI improvement of 50% using PASI 50 at the end of 360 days. Timepoint: Period of Study Achievable Targets 0-6 months Enrolment and follow up Upto 18 months Follow up the cases 18-24 months Data compilation & analysis ;manuscript preparation of the study Regular clinical assessments as per case requirements | — |
Countries
India
Contacts
Public ContactDr Anupriya
AIIMS Bibinagar
Outcome results
None listed